Asthma News: Breaking Asthma News, Comments and Articles. - Page: 5

19:34 EDT 1st September 2014 | BioPortfolio

Asthma News - Page: 5Twitter RSS

Read the latest Asthma News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Asthma.

Search or Follow Our Asthma - Page: 5 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Asthma - Page: 5 News.
You can also follow our Asthma - Page: 5 news stories on Twitter: @asthma_bio

Showing "asthma" News Articles 101 to 125 of 1,100+

Thursday 14th August 2014

State Highlights: Mass. Hospitals See 70% Jump In Mistakes; Changes Coming To Md.'s State Employee Health Plan

A selection of health policy stories from Massachusetts, Maryland, Texas, California, Wisconsin and Illinois.  The Boston Globe: Mass. Hospitals’ Mistakes List Widens Massachusetts acute-care hospitals reported 753 serious medical errors and other patient injuries last year, a 70 percent annual jump that health officials attributed mostly to expanded definitions of what constitutes...

State Highlights: Mass. Hospitals See 70% Jump In Mistakes

A selection of health policy stories from Massachusetts, Maryland, Texas, California, Wisconsin and Illinois.  The Boston Globe: Mass. Hospitals’ Mistakes List Widens Massachusetts acute-care hospitals reported 753 serious medical errors and other patient injuries last year, a 70 percent annual jump that health officials attributed mostly to expanded definitions of what constitutes...

AstraZeneca Advances Tralokinumab for Severe Asthma to Phase III

AstraZeneca announced the start of the Phase III program for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm.Read more...

Global asthma market to hit $18 billion by 2021 boosted by biologics

The market for asthma drugs is predicted to reach $18 billion by 2021, according to new research from analyst firm Datamonitor Healthcare.

ZAI Lab, Sanofi ink agreement for chronic respiratory disease compounds

ZAI Lab, a biotech company in China, has entered into a global licensing agreement with Sanofi for two novel compounds for the potential treatment of chronic respiratory diseases including chronic obstructive pulmonary disease (COPD), asthma and idi...

Retroscreen Virology brings in more than £33mln to advance business

Rapidly growing  life sciences firm Retroscreen Virology Group (LON:RVG) has brought in over £33 million through a  share placing to develop the business. The AIM firm issued around 12,9 mln shares at 260p pence a pop - that's an 18.8...

Genetic signal prevents immune cells from turning against the body

When faced with pathogens, the immune system summons a swarm of cells made up of soldiers and peacekeepers. The peacekeeping cells tell the soldier cells to halt fighting when invaders are cleared. Without this cease-fire signal, the soldiers, known ...

AstraZeneca's asthma drug enters late-stage trials

AstraZeneca said it is initiating late-stage trials of its experimental severe-asthma drug tralokinumab, which generated posi -More- 

AZ severe asthma drug tralokinumab goes into Phase III

AZ severe asthma drug tralokinumab goes into Phase III

Publication by KaloBios and Collaborators Shows EphA3 as Target for Highly Selective Anticancer Therapy

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the publication of preclinical findings describing EphA3 as a novel target expressed by a broad range of human tumors,  and whose activation can lead to the selective disruption of the tumor microenvironment and newly formed tumor blood vessels. The expression and func...

Associations of sugar-containing beverages with asthma prevalence in 11-year-old children: the PIAMA birth cohort

AstraZeneca starts final-stage tests on severe asthma drug

LONDON, Aug 14 (Reuters) - AstraZeneca said on Thursday it was starting final-stage Phase III clinical trials for its experimental drug tralokinumab as a treatment for severe asthma.

Occupational Asthma Remains Difficult to Diagnose

A conclusive diagnosis requires information on workplace exposure. Medscape Medical News

Wednesday 13th August 2014

Rigel cuts two more programs from pipeline

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) discontinued development of R348 to treat dry eye disease after the compound missed the primary endpoint of improving corneal fluorescein staining score from baseline to week 12 vs. placebo in a Phase II trial...

Registration Now Open for Scale the Strat on March 1, 2015 at Stratosphere Tower in Las Vegas

7th Annual Extreme Stair Climb Benefits American Lung Association in Nevada Las Vegas, Nevada (PRWEB) August 13, 2014 The first step is easy. It is the next 1,455 steps that are the challenge. Yes, you read that right. One thousand four hundred fifty-five steps. Registration is now open for Scale the Strat on Sunday, March 1, 2015. Those wanting to climb all 108 floors of stairs inside the iconi...

Physiological variables best predict adult asthma phenotypes

Physiological variables are more consistent predictors of adult asthma phenotypes than inflammatory biomarkers, an international team of researchers suggests.

Fluticasone furoate effective in moderate-to-severe asthma

Once daily fluticasone furoate, used at a dose of 100 µg or 200 µg, provides substantial improvements in lung function and asthma control for patients with uncontrolled moderate-to-severe asthma, phase III trial results show.

Lloyds Pharmacy Limited - Strategic SWOT Analysis Review

Recently added to the BioPortfolio report store, Lloyds Pharmacy Limited - Strategic SWOT Analysis Review is a new report from GlobalData published on 2014-08-10. This 15-page report is available in PDF from $300. Summary Lloyds Pharmacy Limited (Lloydspharmacy) is a pharmacy product retailer. The company offers a various range of products and services to its customers. Its product portfolio inc...

Teijin Pharma Limited - Strategic SWOT Analysis Review

Recently added to the BioPortfolio report store, Teijin Pharma Limited - Strategic SWOT Analysis Review is a new report from GlobalData published on 2014-08-10. This 15-page report is available in PDF from $300. Summary Teijin Pharma Limited (Teijin) is a specialty healthcare company. It manufactures and markets pharmaceuticals and medical devices for the treatment of bone and joint diseases, re...

Microlife Corporation (4103) - Financial and Strategic SWOT Analysis Review

Recently added to the BioPortfolio report store, Microlife Corporation (4103) - Financial and Strategic SWOT Analysis Review is a new report from GlobalData published on 2014-08-10. This 25-page report is available in PDF from $300. Summary Microlife Corporation (Microlife) is a digital medical measurement systems and healthcare service provider. It develops medical measurement products and serv...

Hi-Tech Pharmacal Co., Inc. (HITK) - Financial and Strategic SWOT Analysis Review

Recently added to the BioPortfolio report store, Hi-Tech Pharmacal Co., Inc. (HITK) - Financial and Strategic SWOT Analysis Review is a new report from GlobalData published on 2014-08-10. This 25-page report is available in PDF from $300. Summary Hi-Tech Pharmacal Co., Inc. (Hi-Tech Pharmacal) is a pharmaceutical company. It develops, manufactures and markets generic prescription, over-the-count...

New State "Honor Roll" Reveals New Standards, New States and New Outlooks for Asthma & Allergy School Policies

WASHINGTON, Aug. 13, 2014 /PRNewswire-USNewswire/ -- In just a few weeks, schools will be back in session for the millions of students with asthma and food allergies. So what are schools doing to protect students and teachers with these chronic diseases? Today the Asthma and Allergy Foundation of America (AAFA) revealed its 2014 State Honor Roll™ of Asthma and Allergy Policies for Schoo...

Tuesday 12th August 2014

Sanofi licenses preclinical compounds to China's Zai Lab

Sanofi (Euronext:SAN; NYSE:SNY) granted newco Zai Laboratory Inc. (Shanghai, China) a worldwide license to develop, manufacture and commercialize two preclinical compounds to treat chronic respiratory diseases, including chronic obstructive pulmonary...

Nurtur® Receives NCQA Patient and Practitioner Oriented Accreditation for Disease Management Programs

Accreditation demonstrates Nurtur as a best-in-class provider of Disease Management programs that meet the nation’s highest standards for value and quality. Farmington, CT (PRWEB) August 12, 2014 Nurtur, the health and wellness company serving employers, health plans and government programs, announced today that it has proudly received its renewed three-year Patient and Practitioner Oriented Ac...

Rite Aid Encourages Customers to Shield Themselves from the Flu

Flu Shots Now Available at Rite Aid Pharmacies Nationwide Rite Aid’s Workplace Flu Shot Clinic and Voucher Programs Return Rite Aid Corporation (NYSE: RAD) announced today that seasonal flu shots are now available at Rite Aid pharmacies nationwide. Customers can visit any Rite Aid pharmacy to receive a flu shot from a certified immunizing Ri...


Search BioPortfolio:
Advertisement
Advertisement

News Quicklinks